H5N1 VLP pandemic influenza vaccine: Additional Phase I/IIa data

Additional data from a double-blind, placebo-controlled, U.S. Phase I/Ila trial (H5N1 VLP-1) showed that 64% of volunteers receiving two 90 µg doses of Novavax's vaccine achieved a 4-fold or greater i...